Welcome to our dedicated page for Haleon plc SEC filings (Ticker: HLNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Haleon plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Haleon plc's regulatory disclosures and financial reporting.
Haleon plc announced that its 2026 half year results statement for the year ending 31 December 2026 is now available on its investor website and through the UK Financial Conduct Authority’s National Storage Mechanism.
The Board declared an H1 2026 interim dividend of 2.4 pence per ordinary share, a 9% increase on the 2025 interim dividend and in line with the policy of paying about one third of the prior full-year dividend at the interim stage. The dividend is expected to be paid on 17 September 2026 to holders of ordinary shares and ADS on the register as of 14 August 2026, with ex-dividend dates of 13 August 2026 for ordinary shares and 14 August 2026 for ADS. A Dividend Reinvestment Programme is available with an election deadline of 28 August 2026. Management will provide a recorded results presentation and a Q&A session for analysts and shareholders on 30 July 2026.
Haleon plc reported H1 2026 revenue of £5,602m, up 2.2% on a reported basis and 2.6% organically. Reported gross margin rose to 65.9%, while adjusted gross margin reached 66.5%. Adjusted operating profit increased to £1,364m, with margin expanding to 24.3%, although reported operating profit declined 2.6% to £1,172m due mainly to restructuring costs linked to an operating model change.
Reported diluted EPS fell 4.5% to 8.5p, but adjusted diluted EPS rose 12.0% to 10.3p, helped by higher adjusted profit and a smaller share count. Net cash from operating activities was £1,044m and free cash flow £769m. Net debt stood at £7.5bn (2.5x net debt/adjusted EBITDA) after repaying an €850m bond, and £457m of a £500m 2026 share buyback had been completed. An interim dividend of 2.4p per share, 9% above 2025, was declared.
Operationally, 73% of the business gained or maintained market share, with strong growth in Oral Health and Pain Relief partly offset by a decline in Respiratory Health following a weak cold and flu season. Guidance for 2026 is unchanged, with expected organic revenue growth of 3–5% and high single-digit adjusted operating profit growth at constant currency, supported by ongoing productivity programmes and a medium-term goal of 50–80bps annual adjusted gross margin expansion.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of common stock of Haleon plc. BlackRock reports beneficial ownership of 745,718,619 shares of Haleon common stock, representing 8.5% of the class.
BlackRock has sole voting power over 691,385,758 shares and sole dispositive power over 745,718,619 shares, with no shared voting or dispositive power reported. Various underlying clients or other persons have rights to dividends or sale proceeds from these shares, but no such person is reported to hold more than five percent of Haleon’s outstanding common shares.
Haleon plc reported that Chief Financial Officer Dawn Allen received a vesting of performance-based share awards under the Haleon Performance Share Plan. On 30 June 2026, she acquired 283,193.151771 ordinary shares at nil cost, reflecting achievement of performance conditions through 31 December 2025 and continued employment requirements.
As part of the same event, 133,300.732432 shares were automatically sold on the London Stock Exchange at £3.523867 per share to meet tax liabilities. The remaining shares are subject to Haleon’s shareholding requirements, as well as malus and clawback provisions designed to align executive rewards with long-term performance.
Haleon plc reports its share capital and voting rights position. As at 30 June 2026, the company has issued 8,820,906,422 ordinary shares of £0.01 each, of which 12,006,714 are held as treasury shares. This leaves 8,808,899,708 ordinary shares with voting rights. Shareholders and others with notification obligations are instructed to use this voting-rights figure as the denominator when assessing whether they must notify their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reports it has purchased 6,992,435 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases were made on 22 and 23 June 2026 across the London Stock Exchange, Cboe UK venues and Aquis at volume weighted average prices around 332–334 pence per share.
After settlement, Haleon’s registered share capital is 8,820,906,422 ordinary shares, including 12,006,714 treasury shares. The number of ordinary shares with voting rights is now 8,808,899,708, which shareholders can use when assessing disclosure thresholds under UK transparency rules.
Haleon plc reported that it purchased 14,288,204 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The shares were bought on several UK trading venues between 15 and 18 June 2026 at volume-weighted average prices around 331–334 pence per share.
After settlement of these transactions, Haleon’s registered share capital is 8,827,898,857 ordinary shares, of which 12,022,709 are held as treasury shares. This leaves 8,815,876,148 ordinary shares with voting rights, a figure shareholders can use to assess whether disclosure thresholds are met under UK transparency rules.
Haleon plc reported that it bought back 565,285 ordinary shares of £0.01 each on 8 June 2026 for cancellation under its share buyback programme announced on 12 March 2026. The shares were purchased on the London Stock Exchange.
The highest price paid was 335.0000p per share, the lowest was 330.5000p, and the volume-weighted average price was 331.9552p. After this transaction, registered share capital is 8,842,187,061 ordinary shares, including 12,025,084 held as treasury shares.
The number of ordinary shares with voting rights is now 8,830,161,977. Haleon notes that shareholders can use this figure when assessing whether they must notify their holdings under the UK Disclosure Guidance and Transparency Rules.
Haleon plc reported recent activity under its share buyback programme, announcing the purchase of 16,585,448 ordinary shares of £0.01 each for cancellation between 1 and 4 June 2026 across the London Stock Exchange, CBOE (UK) venues and Aquis.
Following settlement, Haleon’s registered share capital is 8,842,752,346 ordinary shares, including 12,063,502 treasury shares. The resulting number of ordinary shares with voting rights is 8,830,688,844, a figure shareholders can use when assessing disclosure thresholds under UK transparency rules.
Haleon plc reported its updated share capital and voting rights position. As at 31 May 2026, the company had 8,859,337,794 ordinary shares of £0.01 each in issue, of which 12,076,964 were held as treasury shares.
This leaves 8,847,260,830 ordinary shares with voting rights. Haleon explains that this voting-rights figure should be used by shareholders and other obliged investors as the denominator when calculating whether they must notify holdings or changes in holdings under the FCA’s Disclosure Guidance and Transparency Rules.